WOBURN, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient delivery, access, safety and convenience, today announced that the company will present at the upcoming Biotech Showcase Conference on Tuesday, January 10, 2023 at 9:00 AM PT in San Francisco, CA.
The Company will also host one-on-one meetings with investors from Monday, January 9 through Wednesday January 11.
This year, registered Biotech Showcase attendees can view the company presentation live. Also, attendees can view recorded presentations at their convenience with 24x7 on-demand access, when scheduling does not allow viewing during the main event week.
A live webcast of the presentation and a replay of the presentation will be available for 6 months under the “Events & Presentations” page in the Investor Relations section of the Company’s website at https://ir.comeralifesciences.com/news-events/events
About Comera Life Sciences
Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The goal of this approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen.
To learn more about the Comera Life Sciences mission, as well as the proprietary SQore™ platform, visit https://comeralifesciences.com/.
Contacts
Comera Investor
John Woolford
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Comera Press
Jon Yu
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.00 |
| Daily Volume: | 0 |
November 13, 2023 November 09, 2023 October 16, 2023 August 16, 2023 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
